Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-24-049069
Filing Date
2024-04-26
Accepted
2024-04-26 16:01:20
Documents
25
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A cere-20231231.htm   iXBRL 10-K/A 1920299
2 EX-31.3 cere-ex31_3.htm EX-31.3 8233
3 EX-31.4 cere-ex31_4.htm EX-31.4 8344
4 GRAPHIC img33056374_0.jpg GRAPHIC 2313
5 GRAPHIC img33056374_1.jpg GRAPHIC 2818
6 GRAPHIC img33056374_2.jpg GRAPHIC 22487
7 GRAPHIC img33056374_3.jpg GRAPHIC 22390
8 GRAPHIC img33056374_4.jpg GRAPHIC 1669
9 GRAPHIC img33056374_5.jpg GRAPHIC 23156
10 GRAPHIC img33056374_6.jpg GRAPHIC 22831
11 GRAPHIC img33056374_7.jpg GRAPHIC 22936
12 GRAPHIC img33056374_8.jpg GRAPHIC 20742
13 GRAPHIC img33056374_9.jpg GRAPHIC 16741
14 GRAPHIC img33056374_10.jpg GRAPHIC 3597043
15 GRAPHIC img33056374_11.jpg GRAPHIC 3501
  Complete submission text file 0000950170-24-049069.txt   12112700

Data Files

Seq Description Document Type Size
16 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cere-20231231.xsd EX-101.SCH 79820
28 EXTRACTED XBRL INSTANCE DOCUMENT cere-20231231_htm.xml XML 11483
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39311 | Film No.: 24883389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)